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ttp://dx.doi.org/10.1016/j.ajpath.2012.09.025For the greater part of the last century, basic science research has been limited to in vitro studies of
cellular processes and ex vivo tissue examination from suitable animal models of disease. In the last
three decades, however, new techniques have been developed that permit the imaging of live animals
using X-rays, radiotracer emissions, magnetic resonance signals, sound waves and optical ﬂuores-
cence, and bioluminescence. The objective of this review is to provide a broad overview of common
animal imaging modalities, with a focus on positron emission tomography (PET), single photon
emission computed tomography (SPECT), and computed tomography (CT). Important examples,
beneﬁts, and limits of microPET/SPECT/CT technologies in current use, and their central role in
improving our understanding of biological behavior and in facilitating the development of treat-
ments from bench to bedside are included. (Am J Pathol 2013, 182: 319e324; http://dx.doi.org/
10.1016/j.ajpath.2012.09.025)A guest editor acted as editor-in-chief for this manuscript. No person at
Albert Einstein College of Medicine was involved in the peer review
process or ﬁnal disposition of this article.Animal investigation has been an integral component of
biomedical research for the last 100 years, but has been
limited to in vitro studies of cellular processes and ex vivo
tissue examination from suitable animal models of disease.
In the past 30 years, and particularly in the past decade,
improvements in computer hardware and software capabil-
ities have enabled whole-body animal imaging to comple-
ment the traditional in vitro and ex vivo study techniques.
Whole-body imaging using positron emission tomography
(PET), single photon emission computed tomography
(SPECT), and computed tomography (CT) scanning have
revolutionized clinical imaging and with increasing minia-
turization of components, these techniques have become
available to facilitate small animal research as well.
Some of the impetus to develop in vivo imaging has come
from recognition of improvements in imaging technologies
by the National Institute of Biomedical Imaging and Bioen-
gineering (NIBIB), established by the National Institutes of
Health (NIH).1 It has been understood that longitudinal
imaging techniques could permit improvement of the scien-
tiﬁc information obtained by using animals as their own
controls. The NIBIB explicitly announced that “.Smallstigative Pathology.
.animal imaging provides the means to address . the non-
invasive monitoring of biological processes, disease
progression, and response to therapy, with the potential
to provide a natural bridge to the clinical environment and
contribute substantially to the development of hum an medi-
cine.” [Systems and Methods for Small Animal Imaging
(SBIR/STTR), http://grants.nih.gov/grants/guide/rfa-ﬁles/
RFA-EB-03-002.html, last accessed December 6, 2012].
Another part of the impetus has come from the Association
for Assessment and Accreditation of Laboratory Animal Care
(AAALAC). This voluntary organization has given voice to
the growing consensus that animal research should be per-
formed in a humane manner, considering animal welfare as
well as scientiﬁc beneﬁt. AAALAC as well as other state and
federal agencies adhere to the principles of the three
Rsdreplacement, reduction, and reﬁnementdﬁrst articulated
by Russell and Burch.2 In this context, imaging devices are
seen as technical reﬁnements because they are less invasive
Koba et althan older diagnostic and monitoring techniques. The re-
duction of animal sacriﬁce through serial study using the
same animals as their own controls simultaneously permits
improved statistics of paired observations, thus enhancing the
scientiﬁc value of the observations.
Imaging Devices
Magnetic resonance imaging (MRI) on a human and animal
scale was conceived as an imaginative extrapolation from
the use of magnetic resonance spectroscopy performed on
small tissue samples. Optical imaging also was used for
in vitro cellular imaging, but is now available for whole-
animal imaging of ﬂuorescent proteins and bioluminescent
markers. By contrast, other small animal imaging devices
evolved from similar devices ﬁrst used clinically in humans.
CT, PET, and SPECT were ﬁrst applied to human subjects
before technology advanced sufﬁciently to permit minia-
turization for the purpose of imaging small animals.
Superposition of different types of images such as CT and
PET is known as image co-registration and can be per-
formed using software that aligns images obtained on
separate instruments. More recently, hybrid instruments
such as PET/SPECT/CT and PET/MRI have become
available, improving the limitations of separate image
acquisitions. The co-registration technique has been avail-
able in human devices for several years, permitting direct
comparison of anatomical and functional ﬁndings, and
is now also offered on instruments for animal study.
Imaging of living animals offers the following three
signiﬁcant advantages over older methods in biomedical
investigations:
1. By using animals as their own controls, imaging of living
animals reduces the number of animals sacriﬁced,
simultaneously improving statistics, with consequential
scientiﬁc beneﬁt.
2. Diagnostic and therapeutic agents can be developed and
tested on nearly identical molecular synthesis platforms.Figure 1 18F-FDG- PET co-registered with CT of a mouse with metastatic brea
acquired using an Inveon Trimodal PET/SPECT/CT scanner (Siemens Medical Solut
software version 4.0 (Siemens Molecular Imaging, Knoxville, TN). The PET image
metastatic tumor behind the heart, which appears very bright in the PET images
320Imaging and quantiﬁcation of these agents can directly
identify their biodistribution, pharmacodynamics, and
kinetics, thus providing a uniquely straightforward
translational paradigm.
3. By enabling longitudinal studies, imaging of living animals
allows continuous, dynamic, and sometimes nearly instan-
taneous identiﬁcation/quantiﬁcation of disease progression
and, in many cases, treatment.
These capabilities, especially assessing drug efﬁcacy
noninvasively, are major focuses of the NIH/National
Cancer Institute (NCI) and provide value added approaches
to preclinical studies.
PET, SPECT, and CT Devices and Their Applications
PET scanners are in common use in clinical practice
particularly for the diagnosis and management of cancers.
This familiar application is widely performed today using
hybrid PET/CT instruments. The most common radiotracer
used in humans is 18F-2-deoxy-2-ﬂuoro-D-glucose (FDG)
because of its behavior as a glucose congener. This property
allows FDG to provide increased speciﬁcity in evaluation of
a wide variety of aggressive glycolytic cancers, due to their
widespread overexpression of glucose 1 transporters and
of hexokinase, causing FDG-phosphate to be trapped
within cells. SPECT scanners and, more recently, SPECT/
CT scanners are also in common clinical practice using
a wide variety of radiotracers for procedures such as bone
scans, myocardial perfusion imaging, lung perfusion/venti-
lation imaging, hepatobiliary imaging, as well as studies of
any other organ systems. Similar radioactive tracers can be
targeted for in vivo animal imaging in analogous clinical
PET/SPECT/CT devices and by the same physiological
uptake mechanisms. Therefore, administration of radiotracer
molecules, imaged at unrivaled picomolar concentrations,3
provides uniquely noninvasive, nontoxic, quantitative,
longitudinal, functional images of physiological health as
well as diagnosis and mechanisms of disease, obviouslyst cancer in the lungs. Axial (A), coronal (B), and sagittal (C) images were
ions, Malvern, PA) and were co-registered with Inveon Research Workplace
s are in color co-registered with the CT in grayscale. Arrows indicate the
.
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of CT on the same imaging gantry allows precise anatomical
co-registration of functional information with anatomy,
just as in human-scale instruments. Figure 1 shows the
co-registered PET/CT images of a mouse with metastatic
breast cancer in the lungs.
PET, SPECT, CT, and MRI, whether used separately or
together, as described above, now permit high-resolution
anatomical and physiological images in small animal
models of health and disease. CT provides cross-sectional
anatomical imaging with resolution from 100 mm to 50 mm
in living animals. A resolution of 20 mm and better must be
reserved for terminal experiments because ﬁne resolution
comes at the expense of higher radiationeabsorbed dose
effects on animals, requiring sacriﬁce of the animals at the
conclusion of these experiments. Resolution for PET and
SPECT depends on the particulars of instrument speciﬁca-
tions, but 1.3 mm or better is not uncommon for modern
PET, and less than 1.0 mm resolution can be achieved in
certain SPECT conﬁgurations.
The limit of what can be done biologically depends on the
choice and availability of radiotracers. FDG, for PET
studies, is widely used as a surrogate for tumor metabolism
in animal models of cancer to monitor therapeutic responses
noninvasively in serial studies. When coupled with CT,
tumor localization can be improved and tumor heterogeneity
can also be explored. FDG, as a general marker of meta-
bolism, can also be used in cardiac imaging as well as in
inﬂammation and infectious disease.
Sodium ﬂuoride (18F-NaF), a PET bone tracer, in
combination with CT is ideal for studying arthritis and
general bone and joint diseases. 18F-NaF PET is more
sensitive than CT for measuring osteoblast activity, but CT
can measure joint space narrowing and can demonstrate
osteophyte formation and trabecular bone structure. 30-
Deoxy-30-18F-ﬂuorothymidine (18F-FLT) can be used to
measure cell proliferation, making it a good candidate to
monitor stem cell growth, analogous to iododeoxyuridine
used in vitro.
124I, naturally, has a role in evaluating thyroid function as
well as all organs which express the sodium iodide sym-
porter, including breast tissue, choroid plexus, gastric
mucosa, and salivary glands. 64Cu has been used in the
evaluation of Wilson’s disease. Both 124I and 64Cu may be
conjugated to other biological molecules of interest.
The palette of tracers available for SPECT imaging is
even broader as they all are used clinically. 99mTechnetium
(99mTc) is the most widely used radiotracer in the world. It is
a waste product of nuclear reactors (daughter of the decay of
99molybdenum by b decay) and is therefore relatively
inexpensive. It is used to label radiotracers including i)
methylene diphosphate (MDP) for bone and joint imaging;
ii) mebrofenin for hepatocyte function and hepatobiliary
excretion; iii) macroaggregated albumin (MAA) for regional
organ perfusion and especially pulmonary perfusion; and iv)
methyl isobutyl isonitrile (MIBI) for cardiac perfusionThe American Journal of Pathology - ajp.amjpathol.orgexperimental models of ischemic heart disease. MIBI has
also been used to image and localize parathyroid adenomas.
For academic institutions, an on-site or nearby cyclotron
as well as the capacity to synthesize organic molecules
makes possible an almost inﬁnite variety of radiotracers,
especially short-lived compounds labeled with 11C
(20 minute half-life), 13N (10 minutes.), and even 15O
(2 minutes). Brain receptor imaging with 11C raclopride has
achieved wide use for evaluation of schizophrenia due to
dopamine 2 (D2) receptor binding. Tropane derivatives are
used in Parkinson’s disease, and amyloid-seeking labels are
used to monitor Alzheimer’s disease. The variety of uses is
constrained only by the limits of organic chemistry
synthesis, although the expense of cyclotron use and
synthesis is substantial. The potential for neuroscience
imaging is enormous when PET is coupled with MRI to
provide high-resolution anatomy of the brain, function
derived from informed use of magnetic sequences, and
metabolism/function from PET tracers.Theranostics Using Radiotracers
Theranostics, combining diagnostics and therapeutics, has
become increasingly important with advances in nanotech-
nology and molecular imaging. In many ways theranostics
is not new to nuclear medicine, as the classic application
of radioactive iodine in both diagnosis4 and therapy5,6 of
thyroid conditions dates to the 1930s and 1940s. More
recent areas of development include targeting neurodegen-
erative diseases, malignancies,7 and infectious diseases
including human immunodeﬁciency virus and crypto-
coccus.8,9 Tracers developed for PET and SPECT may be
coupled with tracers for MRI and optical imaging in animal
work, and then translated into human theranostic agents.
An area of special interest for probe design and thera-
nostic development is cell therapy.10,11 While still undif-
ferentiated, stem cells home to diseased organs and take
their molecular cues from surrounding tissues to develop
into normal tissues, thus offering the potential to repair
damaged organs such as the heart, liver, lung, retina, and
kidney, without requiring organ transplantation. This
potential of stem cell repair remains largely unfulﬁlled;
however, it is at the center of enormous research attention
because of its almost unlimited promise. Before attempting
such studies in humans, translational research using exper-
imental animal models is absolutely essential. Stem cell
therapy has been investigated as a means of recovering
cardiac function resulting from chronic damage caused by
Trypanosoma cruzi infection both in animal models of
Chagas disease and in patients with chagasic cardiomyop-
athy.12,13 Stem cell therapy has also been shown to extend
incubation and survival time in mice infected with a mouse-
adapted prion strain.14 Other investigators have demon-
strated the engraftment of stem cells into the lung in
mice with acute Pseudomonas aeruginosa infection.15321
Koba et alDevelopment of noninvasive methods for tracking the
temporal and spatial homing of these cells to the diseased
tissues is necessary to understand the mechanisms behind
their therapeutic actions.16 A number of studies have re-
ported detection of labeled stem cells in cardiac tissue,
mostly after direct transplantation into the heart.17e23 A
recent study reports the successful labeling of adipose-
derived stem cells with 18F-FDG.24 Multimodal molecular
imaging agents can take advantage of the different strengths
of various imaging technologies such as reported by
Hwang et al.25 In that study, multimodal nanoparticles were
developed for studies using ﬂuorescence, bioluminescence,
PET, and MRI imaging in vivo. To date, most applications
have been nontargeted, and further development of methods
to target cells to speciﬁc tissue types is required to provide
accurate diagnostic staging of disease and to deliver
therapeutics. The targeting of labeled cells or the particles
themselves to identify speciﬁc tissues can be accomplished
by attaching antibodies or peptides or through small
molecule surface modiﬁcation or with targeted reporter
genes.26e28
Exciting areas of development in molecular imaging
probe design include the design of aptamers targeted to
biologically relevant molecules and the development of
activatable molecular probes. The details of these develop-
ments are beyond the scope of this article, but a number of
excellent reviews have been published.29e31 Aptamers,
short single-strand loops of DNA, RNA, or peptides, are
generated by computer proﬁling of random combinations of
nucleotides, ribonucleotides or amino acids, respectively.
Numerous combinations and permutations are possible
depending on aptamer length. Two noteworthy features of
aptamers have attracted considerable attention: i) most of
them provoke little or no immunological reaction in
humans; and ii) they can be designed to target, with
antibody-like speciﬁcity, desirable molecular targets. These
features make them most attractive for development as
theranostic agents for targeted delivery of radiotracers and
nanoparticles. Activatable molecular probes are another area
of interest for development as theranostic agents.32,33 LightFigure 2 A: Aquarium sized for a 40 g goldﬁsh. Representative coronal (B), sa
were acquired using a Concorde R4 microPET scanner (Concorde MicroSystems, Kn
322has been used as a remote-activation mechanism for drug
delivery using photodynamic-, photothermal-, or photo-
triggered chemotherapy for several diseases.33 Activatable
molecular probes, in combination with speciﬁc targeting,
have the potential for application as personalized medical
treatment for each individual patient.Future Directions for Small Animal Imaging
Most small animal imaging studies have focused on
mammalian species, particularly mice and rats. Anesthesia
is typically required during image acquisition; although, in
recent years, special restraining holders for conscious MRI
studies of brain function of rodents have been introduced.
Biological investigations of ray-ﬁnned teleost ﬁsh species,
on the other hand, have yielded important insights into
vertebrate ontologic development (zebraﬁsh), neurological
and retinal physiology (goldﬁsh), and physiological balance
mechanisms (toadﬁsh), among others. Invertebrate species,
especially horseshoe crabs, have also been invaluable
models to promote understanding of blood coagulation and
immune regulation mechanisms. Fish would appear to have
potential value for imaging applications.
However, immobilization of ﬁsh for serial physiological
studies using modern in vivo imaging techniques has proved
to be challenging. For example, ﬁsh can be immobilized by
anesthetizing and suspending them in agar34 or through
injections of muscle relaxants35; however, such studies of
the animal are not appropriate for serial studies over a long
time frame. Furthermore, these methods are not realistic for
physiological PET imaging applications, which may require
a living animal to remain motionless for up to 2 hours. A
small imaging tank for ﬁsh and other aquatic creatures is
feasible36 and is demonstrated in Figure 2. An outstanding
virtue of this technique is that the ﬁsh is restrained safely to
prevent motion artifacts but remains conscious in an aerated,
research aquarium, permitting experiments under physio-
logical conditions. The concept is similar to a ﬂow-through
probe designed for 31P NMR studies of ﬁsh37 and angittal (C), and axial (D) FDG-PET images of the goldﬁsh are shown. Images
oxville, TN).
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tion of the animal before an experiment may be helpful,
whether for imaging or nonimaging applications.
In summary, the NIH has set the value of longitudinal
imaging study as a priority in preclinical research, both as a
means to reduce animal sacriﬁce and to improve science and
statistical power using study animals as their own controls.
MicroPET/SPECT and CT modalities are noninvasive and
offer unique opportunities to study metabolism and function
in small animal models of human disease.Acknowledgments
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